ALB and neoplasm with perivascular epithelioid cell differentiation: In 2005 and 2021, the FDA approved Abraxane, paclitaxel albumin protein‐bound nanoparticles (~130 nm) for intravenous use to treat breast cancer, and Fyarro, sirolimus albumin protein‐bound nanoparticles for intravenous use to treat perivascular epithelioid cell tumor (PEComa), respectively.